DNM1L and type 2 diabetes mellitus: Regarding the use of DRP1 inhibitors as anti-T2D and -cancer agents, further studies should determine long-term effects of targeting mitochondrial dynamics in vivo, and establish the pharmacokinetics and cytotoxicity profiles for mdivi-1.